Right heart catheterization for pulmonary hypertension during the coronavirus disease 2019 pandemic.
Kanza N QaiserJames E LaneAdriano R TonelliPublished in: Pulmonary circulation (2020)
Right heart catheterization is an essential diagnostic modality in the evaluation of pulmonary hypertension. The coronavirus disease 2019 pandemic has resulted in deferral of elective procedures including right heart catheterization. The benefits of proceeding with right heart catheterization, such as further characterization of hemodynamic subtype and severity of pulmonary hypertension, initiation of targeted pulmonary arterial hypertension therapy, as well as further hemodynamic testing, need to be carefully balanced with the risk of potentially exposing both patients and health care personnel to coronavirus disease 2019 infection. This review article aims to provide best clinical practices for safely performing right heart catheterization in pulmonary hypertension patients during the coronavirus disease 2019 pandemic.
Keyphrases
- coronavirus disease
- pulmonary hypertension
- pulmonary arterial hypertension
- pulmonary artery
- end stage renal disease
- healthcare
- heart failure
- respiratory syndrome coronavirus
- ejection fraction
- chronic kidney disease
- atrial fibrillation
- newly diagnosed
- peritoneal dialysis
- patients undergoing
- prognostic factors
- stem cells
- primary care
- bone marrow
- cancer therapy
- drug delivery
- mesenchymal stem cells
- cell therapy
- replacement therapy